A February 2026 peer-reviewed study (Kasher Meron et al.) found an 11% higher fragility fracture risk in GLP-1 users aged 65+ with Type 2 diabetes versus those on other diabetes medications - a retrospective study showing association, not proven causation
is now 7.2 mg per week as of March 2026, following FDA review of the STEP UP trial
Helps fade dark spots and uneven tone
The best choice depends on personal factors such as health needs, cost, insurance coverage, and overall treatment goals
Viral inactivation was less effective at pH 6.5 (11 mM lactic acid), which resulted in 1 log inhibition of infection and required exposure to the acidic environment for 16 hrs
Future efforts should prioritize patient stratification, cost reduction, accessibility, and robust safety monitoring to fully harness the benefits of these groundbreaking therapies